Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption

📅 Add to Calendar! |  🎥 Join Webinar on Zoom

The arrival of GLP-1 medications has been described as one of the most important healthcare innovations in recent years. In this webinar, Jasmin Moshfegh (Imperial College Business School) will present large-scale quasi-experimental evidence on the real-world impacts of GLP-1 adoption.

Using comprehensive Veterans Health Administration data covering 1.4 million diabetic or obese veterans, this study examines how variation in physicians’ prescribing propensities affects patient outcomes. The findings demonstrate substantial improvements in glycemic control and clinically meaningful weight loss among patients whose providers become higher propensity adopters.

The session will also explore the broader implications of GLP-1 adoption for healthcare utilization, medical spending, and health policy, including evidence of heterogeneous impacts across patient groups.

Speaker:

Jasmin Moshfegh is an Assistant Professor in Economics and Public Policy at Imperial College Business School and an applied economist specializing in health economics.

Her research examines physician behavior, healthcare innovation, health inequality, and how public policy shapes the diffusion of and access to new medical technologies. She received her PhD in Health Policy (Economics) from Stanford University in 2024 and subsequently held postdoctoral fellowships at the U.S. Department of Veterans Affairs and the National Cancer Institute at the National Institutes of Health.